Literature DB >> 23690069

Arginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2/β-arrestin1/extracellular-regulated kinase 1/2-dependent pathway in H9c2 cells.

Weizhong Zhu1, Douglas G Tilley, Valerie D Myers, Ryan C Coleman, Arthur M Feldman.   

Abstract

Circulating levels of arginine vasopressin (AVP) are elevated during hypovolemia and during cardiac stress. AVP activates arginine vasopressin type 1A (V(1A))/Gα(q)-coupled receptors in the heart and vasculature and V(2)/Gα(s)-coupled receptors in the kidney. However, little is known regarding the signaling pathways that influence the effects of V(1A) receptor (V(1A)R) activation during cellular injury. Using hypoxia-reoxygenation (H/R) as a cell injury model, we evaluated cell survival and caspase 3/7 activity in H9c2 myoblasts after treatment with AVP. Pretreatment of H9c2 cells with AVP significantly reduced H/R-induced cell death and caspase 3/7 activity, effects that were blocked via both selective V(1A)R inhibition and mitogen-activated protein kinase (MEK1/2) inhibition. AVP increased extracellular-regulated kinase 1/2 (ERK1/2) phosphorylation in a concentration-dependent manner that was sensitive to MEK1/2 inhibition and V(1A)R inhibition, but not V(1B)R or V(2)R inhibition. Discrete elements of the V(1A)/Gα(q)-protein kinase C (PKC) and V(1A)/G protein-coupled receptor kinase (GRK)/β-arrestin signaling cascades were inhibited to dissect the pathways responsible for the protective effects of V(1A)R signaling: Gα(q) (overexpression of Gq-I-ires-green fluorescent protein), PKC (administration of Ro 31-82425; 2-[8-(aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-3-yl]-3-(1-methyl-1H-indol-3-yl)maleimide, HCl, bisindolylmaleimide X, HCl), GRK2 [C-terminal GRK2 peptide overexpression and small interfering RNA (siRNA) knockdown], GRK5 (siRNA knockdown), and β-arrestin1 (siRNA knockdown). These studies demonstrated that both Gα(q)/PKC- and GRK2/β-arrestin1-dependent V(1A)R signaling were capable of inducing ERK1/2 phosphorylation in response to AVP stimulation. However, AVP-mediated protection against H/R was elicited only via GRK2- and β-arrestin1-dependent signaling. These results suggest that activation of the V(1A)R in H9c2 cells mediates protective signaling via a GRK2/β-arrestin1/ERK1/2-dependent mechanism that leads to decreased caspase 3/7 activity and enhanced survival under conditions of ischemic stress.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23690069      PMCID: PMC3716325          DOI: 10.1124/mol.113.086322

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  38 in total

1.  A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.

Authors:  Mihai Gheorghiade; Peter S Pang; Andrew P Ambrosy; Gloria Lan; Philip Schmidt; Gerasimos Filippatos; Marvin Konstam; Karl Swedberg; Thomas Cook; Brian Traver; Aldo Maggioni; John Burnett; Liliana Grinfeld; James Udelson; Faiez Zannad
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

2.  The cardioprotective effect of different doses of vasopressin (AVP) against ischemia-reperfusion injuries in the anesthetized rat heart.

Authors:  Afshin Nazari; Seyed Shahabeddin Sadr; Mahdieh Faghihi; Alireza Imani; Maryam Moghimian
Journal:  Peptides       Date:  2011-11-03       Impact factor: 3.750

3.  Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure.

Authors:  Guido Boerrigter; Michael W Lark; Erin J Whalen; David G Soergel; Jonathan D Violin; John C Burnett
Journal:  Circ Heart Fail       Date:  2011-08-11       Impact factor: 8.790

Review 4.  G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function.

Authors:  Douglas G Tilley
Journal:  Circ Res       Date:  2011-07-08       Impact factor: 17.367

5.  A cell-based phenotypic assay to identify cardioprotective agents.

Authors:  Stephanie Guo; Adam Olm-Shipman; Andrew Walters; William R Urciuoli; Stefanie Devito; Sergiy M Nadtochiy; Andrew P Wojtovich; Paul S Brookes
Journal:  Circ Res       Date:  2012-03-06       Impact factor: 17.367

6.  Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling.

Authors:  Xue Li; Tung O Chan; Valerie Myers; Ibrul Chowdhury; Xue-Qian Zhang; Jianliang Song; Jin Zhang; Jocelyn Andrel; Hajime Funakoshi; Jeffrey Robbins; Walter J Koch; Terry Hyslop; Joseph Y Cheung; Arthur M Feldman
Journal:  Circulation       Date:  2011-07-11       Impact factor: 29.690

Review 7.  Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism.

Authors:  Mitchell H Rosner; Claudio Ronco
Journal:  Congest Heart Fail       Date:  2010-07

Review 8.  GRK2 inhibition in heart failure: something old, something new.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Walter J Koch
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 9.  G protein-coupled receptor kinases in normal and failing myocardium.

Authors:  Zheng Maggie Huang; Jessica I Gold; Walter J Koch
Journal:  Front Biosci (Landmark Ed)       Date:  2011-06-01

10.  Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice.

Authors:  Toonchai Indrambarya; John H Boyd; Yingjin Wang; Melissa McConechy; Keith R Walley
Journal:  Crit Care       Date:  2009-06-23       Impact factor: 9.097

View more
  15 in total

1.  Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia.

Authors:  Adam J Funk; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2014-08-19       Impact factor: 4.939

2.  Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways.

Authors:  Tarsis F Brust; Michael P Hayes; David L Roman; Kevin D Burris; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2014-12-24       Impact factor: 4.030

3.  Vasopressin type 1A receptor deletion enhances cardiac contractility, β-adrenergic receptor sensitivity and acute cardiac injury-induced dysfunction.

Authors:  Melissa A Wasilewski; Laurel A Grisanti; Jianliang Song; Rhonda L Carter; Ashley A Repas; Valerie D Myers; Erhe Gao; Walter J Koch; Joseph Y Cheung; Arthur M Feldman; Douglas G Tilley
Journal:  Clin Sci (Lond)       Date:  2016-09-02       Impact factor: 6.124

4.  Bcl-2-associated athanogene 3 protects the heart from ischemia/reperfusion injury.

Authors:  Feifei Su; Valerie D Myers; Tijana Knezevic; JuFang Wang; Erhe Gao; Muniswamy Madesh; Farzaneh G Tahrir; Manish K Gupta; Jennifer Gordon; Joseph Rabinowitz; Frederick V Ramsey; Douglas G Tilley; Kamel Khalili; Joseph Y Cheung; Arthur M Feldman
Journal:  JCI Insight       Date:  2016-11-17

5.  A novel role of G protein-coupled receptor kinase 5 in urotensin II-stimulated cellular hypertrophy in H9c2UT cells.

Authors:  Cheon Ho Park; Ju Hee Lee; Mi Young Lee; Jeong Hyun Lee; Byung Ho Lee; Kwang-Seok Oh
Journal:  Mol Cell Biochem       Date:  2016-09-09       Impact factor: 3.396

6.  Reactivation of fatty acid oxidation by medium chain fatty acid prevents myocyte hypertrophy in H9c2 cell line.

Authors:  Saifudeen Ismael; R Renuka Nair
Journal:  Mol Cell Biochem       Date:  2020-09-30       Impact factor: 3.396

Review 7.  Arginine vasopressin receptor signaling and functional outcomes in heart failure.

Authors:  Melissa A Wasilewski; Valerie D Myers; Fabio A Recchia; Arthur M Feldman; Douglas G Tilley
Journal:  Cell Signal       Date:  2015-07-30       Impact factor: 4.315

8.  β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling.

Authors:  Douglas G Tilley; Weizhong Zhu; Valerie D Myers; Larry A Barr; Erhe Gao; Xue Li; Jianliang Song; Rhonda L Carter; Catherine A Makarewich; Daohai Yu; Constantine D Troupes; Laurel A Grisanti; Ryan C Coleman; Walter J Koch; Steven R Houser; Joseph Y Cheung; Arthur M Feldman
Journal:  Circulation       Date:  2014-09-09       Impact factor: 29.690

Review 9.  Differential Regulation of GPCRs-Are GRK Expression Levels the Key?

Authors:  Edda S F Matthees; Raphael S Haider; Carsten Hoffmann; Julia Drube
Journal:  Front Cell Dev Biol       Date:  2021-05-24

10.  Overexpression of ß-Arrestin1 in the Rostral Ventrolateral Medulla Downregulates Angiotensin Receptor and Lowers Blood Pressure in Hypertension.

Authors:  Jia-Cen Sun; Bing Liu; Ru-Wen Zhang; Pei-Lei Jiao; Xing Tan; Yang-Kai Wang; Wei-Zhong Wang
Journal:  Front Physiol       Date:  2018-03-28       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.